Janux Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | ||||||||
| Balance at December 31, 2022 | 41,616,260 | $42 | $432,703 | $(1,535) | $(110,470) | 320,740 | ||
| Issuance of common stock and pre-funded common stock warrants, net of $2,495 of issuance costs | 4,153,717 | 4 | 56,526 | — | — | 56,530 | ||
| Exercise of pre-funded common stock warrants | 80,257 | — | — | — | — | — | ||
| Exercise of common stock options | 253,545 | — | 2,246 | — | — | 2,246 | ||
| Shares issued under employee stock purchase plan | 90,574 | — | 772 | — | — | 772 | ||
| Vesting of restricted shares | 58,087 | — | 149 | — | — | 149 | ||
| Stock-based compensation | — | — | 20,005 | — | — | 20,005 | ||
| Unrealized gain on available-for-sale securities, net | — | — | — | 2,200 | — | 2,200 | ||
| Net loss | — | — | — | — | (58,293) | (58,293) | ||
| Balance at December 31, 2023 | 46,252,440 | $46 | $512,401 | $665 | $(168,763) | $344,349 | ||
| Issuance of common stock and pre-funded common stock warrants, net of $45,554 of issuance costs | 11,548,094 | 12 | 697,908 | — | — | 697,920 | ||
| Exercise of common stock options | 1,152,192 | 1 | 14,175 | — | — | 14,176 | ||
| Issuance of common stock upon settlement of restricted stock units | 2,500 | — | — | — | — | — | ||
| Shares issued under employee stock purchase plan | 99,061 | — | 792 | — | — | 792 | ||
| Vesting of restricted shares | 10,319 | — | 20 | — | — | 20 | ||
| Stock-based compensation | — | — | 33,020 | — | — | 33,020 | ||
| Unrealized gain on available-for-sale securities, net | — | — | — | 1,498 | — | 1,498 | ||
| Net loss | — | — | — | — | (68,994) | (68,994) | ||
| Balance at December 31, 2024 | 59,064,606 | $59 | $1,258,316 | $2,163 | $(237,757) | $1,022,781 | ||
| Exercise of pre-funded common stock warrants | 775,698 | 1 | (1) | — | — | — | ||
| Exercise of common stock options | 401,110 | — | 4,070 | — | — | 4,070 | ||
| Issuance of common stock upon settlement of restricted stock units | 15,588 | — | — | — | — | — | ||
| Shares issued under employee stock purchase plan | 127,281 | — | 1,222 | — | — | 1,222 | ||
| Stock-based compensation | — | — | 40,221 | — | — | 40,221 | ||
| Unrealized gain on available-for-sale securities, net | — | — | — | 2,153 | — | 2,153 | ||
| Net loss | — | — | — | (113,625) | (113,625) | |||
| Balance at December 31, 2025 | 60,384,283 | $60 | $1,303,828 | $4,316 | $(351,382) | $956,822 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.